Scholar Rock Holding (SRRK) Gains from Sales and Divestitures (2018 - 2026)
Scholar Rock Holding's quarterly Gains from Sales and Divestitures came in at $275000.0 in Q1 2026, down 76.35% quarter-over-quarter from $1.2 million in Q3 2025.
Scholar Rock Holding has reported Gains from Sales and Divestitures for 9 years, with the latest figure at $275000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures changed N/A year-over-year to $275000.0; the trailing twelve-month figure through Mar 2026 stood at $275000.0 (changed N/A YoY), and the FY2024 full-year result was $679694.0, up 27.41% from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $275000.0, down from $1.2 million in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $1.2 million in Q3 2025, with the low at $49595.0 in Q1 2022.
- Average Gains from Sales and Divestitures over 5 years is $412462.2, with a median of $426393.0 recorded in 2023.
- Year-over-year, Gains from Sales and Divestitures soared 717.61% in 2023 and advanced 22.09% in 2024.
- Tracing SRRK's Gains from Sales and Divestitures over 5 years: stood at $92100.0 in 2022, then surged by 479.22% to $533460.0 in 2023, then grew by 27.41% to $679694.0 in 2024, then surged by 71.09% to $1.2 million in 2025, then plunged by 76.35% to $275000.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $275000.0 (Q1 2026), $1.2 million (Q3 2025), and $679694.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 275,000.00 |
| Mar 31, 2026 | 275,000.00 |
| Sep 30, 2025 | 1.16 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Dec 31, 2024 | 679,694.00 |
| Dec 31, 2024 | 679,694.00 |
| Sep 30, 2024 | 649,559.00 |
| Sep 30, 2024 | 649,559.00 |
| Jun 30, 2024 | 601,170.00 |
| Jun 30, 2024 | 601,170.00 |
| Mar 31, 2024 | 360,373.00 |
| Mar 31, 2024 | 360,373.00 |
| Dec 31, 2023 | 533,460.00 |
| Dec 31, 2023 | 533,460.00 |
| Sep 30, 2023 | 516,703.00 |
| Sep 30, 2023 | 516,703.00 |
| Jun 30, 2023 | 492,413.00 |
| Jun 30, 2023 | 492,413.00 |
| Mar 31, 2023 | 219,378.00 |
| Mar 31, 2023 | 219,378.00 |
| Dec 31, 2022 | 92,100.00 |
| Dec 31, 2022 | 92,100.00 |
| Sep 30, 2022 | 81,913.00 |
| Sep 30, 2022 | 81,913.00 |
| Jun 30, 2022 | 60,226.00 |
| Jun 30, 2022 | 60,226.00 |
| Mar 31, 2022 | 49,595.00 |
| Mar 31, 2022 | 49,595.00 |
| Dec 31, 2021 | 57,969.00 |
| Dec 31, 2021 | 57,969.00 |
| Sep 30, 2021 | 53,584.00 |
| Sep 30, 2021 | 53,584.00 |
| Jun 30, 2021 | 48,582.00 |
| Jun 30, 2021 | 48,582.00 |
| Mar 31, 2021 | 24,283.00 |
| Mar 31, 2021 | 24,283.00 |
| Dec 31, 2020 | 202,381.00 |
| Dec 31, 2020 | 202,381.00 |
| Sep 30, 2020 | 174,234.00 |
| Sep 30, 2020 | 174,234.00 |
| Jun 30, 2020 | 133,704.00 |
| Jun 30, 2020 | 133,704.00 |
| Mar 31, 2020 | 75,296.00 |
| Mar 31, 2020 | 75,296.00 |
| Dec 31, 2019 | 357,604.00 |
| Dec 31, 2019 | 357,604.00 |
| Sep 30, 2019 | 271,062.00 |
| Sep 30, 2019 | 271,062.00 |
| Jun 30, 2019 | 181,274.00 |
| Jun 30, 2019 | 181,274.00 |
| Mar 31, 2019 | 90,500.00 |
| Mar 31, 2019 | 90,500.00 |
| Dec 31, 2018 | 547,786.00 |
| Dec 31, 2018 | 547,786.00 |
| Sep 30, 2018 | 353,549.00 |
| Sep 30, 2018 | 353,549.00 |
| Jun 30, 2018 | 216,011.00 |
| Jun 30, 2018 | 216,011.00 |